

August 11, 2022

The Secretary Listing Department, BSE Limited, 1 st Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400001 Scrip Code: 540975	The Manager, Listing Department, The National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (East), Mumbai 400051 Scrip Symbol: ASTERDM
---	--

Dear Sir/Madam,

Sub:

- 1. Outcome of Board Meeting held on August 11, 2022, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**
- 2. The unaudited financial results for the quarter ended June 30, 2022 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we wish to inform you that:

1. The Meeting of the Board of Directors commenced at 03:00 pm (IST) and concluded at 06:45 pm (IST).
2. The unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2022 together with the Limited Review Report has been reviewed by the Audit Committee and considered and approved by the Board of Directors, has been enclosed herewith as **Annexure-1**.
3. Publication of the results in the Newspaper is being done as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above said information on record as per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thank you

For **Aster DM Healthcare Limited**




Hemish Purushottam
Company Secretary and Compliance Officer

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ASTER DM HEALTHCARE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Aster DM Healthcare Limited ("the Company"), for the quarter ended 30 June 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted, as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Deloitte Haskins & Sells
Chartered Accountants
(Firm's Registration No. 008072S)



Jaideep S. Trasi
(Partner)
(Membership No. 211095)
(UDIN: 22211095AOVAGY2963)

Kochi, 11 August 2022

Aster DM Healthcare Limited
CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -I, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Statement of unaudited standalone financial results for the quarter ended 30 June 2022

Particulars	Quarter ended		Year ended	
	30 June 2022	31 March 2022 (refer Note 5)	30 June 2021	31 March 2022
	(Unaudited)		(Audited)	
1 Income				
Revenue from operations	327.68	290.79	252.12	1,116.47
Other income	9.08	54.54	7.40	82.20
Total income	336.76	345.33	259.52	1,198.67
2 Expenses				
Purchase of medicines and consumables	75.41	64.68	80.68	277.64
Changes in inventories	(3.40)	1.39	(9.01)	(4.10)
Professional fees to consultant doctors	74.66	67.29	55.94	248.24
Laboratory outsourcing charges	9.75	10.93	9.85	44.74
Employee benefits expenses	50.92	39.87	43.38	172.09
Finance costs	10.98	11.42	10.50	44.02
Depreciation and amortisation expenses	23.97	24.47	24.65	98.72
Other expenses	64.59	62.63	50.95	227.36
Total expenses	306.88	282.68	266.94	1,108.71
3 Profit/ (loss) before tax (1-2)	29.88	62.65	(7.42)	89.96
4 Tax expense				
Current tax	-	-	-	-
Current tax for earlier years	-	-	-	-
Deferred tax	-	(0.22)	-	(0.22)
Total tax expense	-	(0.22)	-	(0.22)
5 Profit/(loss) for the period / year (3-4)	29.88	62.87	(7.42)	90.18
6 Other comprehensive income / (loss) for the period / year				
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Remeasurement of net defined benefit liability	-	0.68	-	0.68
Income tax relating to items that will not be reclassified to profit or loss	-	(0.22)	-	(0.22)
Other comprehensive income / (loss), net of taxes	-	0.46	-	0.46
7 Total comprehensive income / (loss) (5+6)	29.88	63.33	(7.42)	90.64
8 Paid-up equity share capital (Face value of INR 10 each)	497.27	497.22	497.11	497.22
9 Other equity				2,457.99
10 Earnings per share (Face value of INR 10 each)				
Basic (in INR)	0.60	1.26	(0.15)	1.81
Diluted (in INR)	0.60	1.26	(0.15)	1.81

See accompanying notes to the statement of standalone financial results



Notes to the statement of unaudited standalone financial results:

- 1) The statement of unaudited standalone financial results ('the Statement') of Aster DM Healthcare Limited ('the Company') for the quarter ended 30 June 2022 has been reviewed by the Audit Committee and approved by the Board of Directors on 11 August 2022. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The report of the statutory auditor is unmodified.
- 2) The Statement has been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.
- 3) In accordance with Ind AS 108, Operating Segments, segment information has been provided in the statement of consolidated financial results of the Company and therefore no separate disclosure on segment information is given in the statement of standalone financial results.
- 4) The Indian Parliament has approved the Code on Social Security, 2020 and Code on Wages, 2019 ['Codes'] relating to employee benefits during employment and post-employment benefits in September 2020 and the same has received Presidential Assent. The Codes have been published in the Gazette of India. However, the date on which the Codes will come into effect has not yet been notified. The Company will give appropriate impact in its standalone financial results in the period in which the Code becomes effective and the related rules are published.
- 5) The figures for the quarters ended 31 March 2022 are balancing figures between audited figures in respect of year ended 31 March 2022 and the unaudited published figures in respect of nine months ended 31 December 2021, which was subjected to limited review by the Statutory Auditors.
- 6) The Board of Directors ('Board') at their meeting held on 28 March 2022 constituted a Committee of Independent Directors ('Committee') of the Board to review the corporate structure of the Company and explore options for enhancing value ('Restructuring'). On 10 June 2022, the Board has provided their approval for appointment of the bankers to explore potential restructuring options which present an opportunity to unlock value for the Company and its stakeholders. Appropriate intimations and impact/ disclosures, if any, would be made as and when any conclusions are arrived at and approved by the Board.
- 7) Statement of unaudited standalone and consolidated financial results are available for perusal at the website of the Company and the stock exchanges.

for and on behalf of the Board of Directors of
Aster DM Healthcare Limited
CIN : L85110KA2008PLC147259

Dr. Azad Moopen
Chairman and Managing Director
DIN: 00159403
Kochi
11 August 2022



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ASTER DM HEALTHCARE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Aster DM Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its associates for the quarter ended 30 June 2022 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
5. The Statement includes the results of the entities as provided in Annexure 1.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

9/5

7. We did not review the interim financial information of 54 subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of INR 2,010.48 crores for the quarter ended 30 June 2022, total net profit after tax of INR 54.18 crores for the quarter ended 30 June 2022 and total comprehensive income INR 54.18 crores for the quarter ended 30 June 2022 as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

8. The unaudited consolidated financial results includes the interim financial information of 12 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of INR 50.83 crores for the quarter ended 30 June 2022, total net profit after tax of INR 1.79 crores for the quarter ended 30 June 2022 and total comprehensive income of INR 1.79 crores for the quarter ended 30 June 2022, as considered in the Statement. The unaudited consolidated financial results also includes the Group's share of net loss after tax of INR 0.39 crores for the quarter ended 30 June 2022 and total comprehensive loss of INR 0.39 crores for the quarter ended 30 June 2022, as considered in the Statement, in respect of 8 associates whose interim financial information have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)



Jaideep S. Trasi

Partner

(Membership No. 211095)
(UDIN: 22211095AOVAMN1244)

Kochi, 11 August 2022

Annexure – 1 to the Independent Auditor's Review Report

SI No	Entity	Relationship	Country of incorporation
1	Aster DM Healthcare Limited	Parent	India
2	DM Med City Hospitals (India) Private Limited	Subsidiary	India
3	Ambady Infrastructure Private Limited	Subsidiary	India
4	Aster DM Healthcare (Trivandrum) Private Limited	Subsidiary	India
5	Malabar Institute of Medical Sciences Limited	Subsidiary	India
6	Prerana Hospital Limited	Subsidiary	India
7	Sri Sainatha Multispeciality Hospitals Private Limited	Subsidiary	India
8	Dr. Ramesh Cardiac and Multispeciality Hospitals Private Limited	Subsidiary	India
9	Aster Clinical Lab LLP	Subsidiary	India
10	Hindustan Pharma Distributors Private Limited	Subsidiary	India
11	Affinity Holdings Private Limited	Subsidiary	Mauritius
12	EMED Human Resources India Private Limited	Step down Subsidiary	India
13	Ezhimala Infrastructure LLP	Step down Subsidiary	India
14	Warseps Healthcare LLP	Step down Subsidiary	India
15	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
16	Aster Ramesh Duhita LLP	Step down Subsidiary	India
17	Komali Fertility Centre LLP (earlier Ramesh Fertility Centre LLP)	Step down Subsidiary	India
18	Aster Caribbean Holdings Limited	Step down Subsidiary	Cayman Island
19	Aster Cayman Hospital Limited	Step down Subsidiary	Cayman Island
20	Aster DM Healthcare FZC	Step down Subsidiary	UAE
21	Aster Hospital Sonapur L.L.C	Step down Subsidiary	UAE
22	Radiant Healthcare L.L.C	Step down Subsidiary	UAE
23	Aster Day Surgery Centre LLC	Step down Subsidiary	UAE
24	DM Healthcare (L L C)	Step down Subsidiary	UAE
25	Wahat Al Aman Home Health Care L.L.C.	Step down Subsidiary	UAE
26	Aster Grace Nursing and Physiotherapy LLC	Step down Subsidiary	UAE
27	Aster Pharmacies Group LLC	Step down Subsidiary	UAE
28	New Aster Pharmacy DMCC	Step down Subsidiary	UAE
29	Aster DCC Pharmacy LLC	Step down Subsidiary	UAE
30	Aster Al Shafar Pharmacies Group LLC	Step down Subsidiary	UAE
31	Rafa Pharmacy LLC	Step down Subsidiary	UAE
32	Aster Pharmacy LLC, AUH	Step down Subsidiary	UAE
33	Med Shop Drugs Store LLC	Step down Subsidiary	UAE
34	Alfa Drug Store LLC	Step down Subsidiary	UAE
35	Alfa One Drug Store LLC	Step down Subsidiary	UAE
36	Alfaone FZ-LLC	Step down Subsidiary	UAE
37	DM Pharmacies LLC	Step down Subsidiary	UAE
38	Aster Opticals LLC	Step down Subsidiary	UAE
39	Medcare Hospital (L.L.C)	Step down Subsidiary	UAE
40	Premium Healthcare Limited	Step down Subsidiary	UAE
41	Dr. Moopens Healthcare Management Services LLC	Step down Subsidiary	UAE
42	Eurohealth Systems FZ LLC	Step down Subsidiary	UAE

95

SI No	Entity	Relationship	Country of incorporation
43	Al Rafa Investments Limited	Step down Subsidiary	UAE
44	Al Rafa Holdings Limited	Step down Subsidiary	UAE
45	Alfa Investments Limited	Step down Subsidiary	UAE
46	Active Holdings Limited	Step down Subsidiary	UAE
47	Al Rafa Medical Centre LLC	Step down Subsidiary	UAE
48	Dar Al Shifa Medical Centre LLC	Step down Subsidiary	UAE
49	Aster Primary Care LLC	Step down Subsidiary	UAE
50	Modern Dar Al Shifa Pharmacy LLC	Step down Subsidiary	UAE
51	Harley Street LLC	Step down Subsidiary	UAE
52	Harley Street Pharmacy LLC	Step down Subsidiary	UAE
53	Harley Street Medical Centre LLC	Step down Subsidiary	UAE
54	Harley Street Dental LLC	Step down Subsidiary	UAE
55	Grand Optics LLC	Step down Subsidiary	UAE
56	Zahrat Al Shefa Medical Center L.L.C	Step down Subsidiary	UAE
57	Samary Pharmacy LLC	Step down Subsidiary	UAE
58	Metro Meds Pharmacy L.L.C	Step down Subsidiary	UAE
59	Metro Medical Center L.L.C	Step down Subsidiary	UAE
60	Symphony Healthcare Management Services LLC	Step down Subsidiary	UAE
61	E-Care International Medical Billing Services Co. LLC	Step down Subsidiary	UAE
62	Al Raffah Hospital LLC	Step down Subsidiary	Oman
63	Al Raffah Pharmacies Group LLC	Step down Subsidiary	Oman
64	Oman Al Khair Hospital L.L.C	Step down Subsidiary	Oman
65	Dr. Moopen's Healthcare Management Services WLL	Step down Subsidiary	Qatar
66	Welcare Polyclinic W.L.L	Step down Subsidiary	Qatar
67	Dr. Moopens Aster Hospital WLL	Step down Subsidiary	Qatar
68	Sanad Al Rahma for Medical Care LLC	Step down Subsidiary	Kingdom of Saudi Arabia
69	Aster DM Healthcare WLL (earlier Aster DM Healthcare SPC)	Step down Subsidiary	Bahrain
70	Orange Pharmacies LLC	Step down Subsidiary	Jordan
71	Al Shafar Pharmacy LLC, AUH	Step down Subsidiary	UAE
72	Aster DM Healthcare INC	Step down Subsidiary	Philippines
73	Aster Medical Centre LLC	Step down Subsidiary	UAE
74	Aster Kuwait Pharmaceuticals and Medical Equipment Company W.L.L	Step down Subsidiary	Kuwait
75	MIMS Infrastructure and Properties Private Limited	Associates	India
76	Alfaone Medicals Private Limited	Associates	India
77	Alfaone Retail Pharmacies Private Limited	Associates	India
78	Mindriot Research and Innovation Foundation	Associates	India
79	Aries Holdings FZC	Associates	UAE
80	AAQ Healthcare Investments LLC	Associates	UAE
81	Aries Investments LLC	Associates	UAE
82	Al Mutamaizah Medcare Healthcare Investment Co. LLC	Associates	UAE

95

Aster DM Healthcare Limited
CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -I, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Statement of unaudited consolidated financial results for the quarter ended 30 June 2022

(Amount in INR crores)

Particulars	Quarter ended (Unaudited)			Year ended
	30 June 2022	31 March 2022	30 June 2021	31 March 2022 (Audited)
	(refer note 5)			
1 Income				
Revenue from operations	2,662.12	2,727.79	2,371.59	10,253.28
Other income (refer note 3)	37.27	21.98	8.04	50.66
Total income	2,699.39	2,749.77	2,379.63	10,303.94
2 Expenses				
Purchase of medicines and consumables	917.75	758.75	804.99	3,068.46
Changes in inventories	(105.84)	(55.33)	(90.90)	(176.69)
Professional fees to consultant doctors	227.76	212.11	187.72	814.77
Laboratory outsourcing charges	15.95	54.83	73.11	254.73
Employee benefits expense	939.41	872.30	757.08	3,264.46
Finance costs	68.80	62.24	66.46	257.02
Depreciation and amortisation expenses	174.96	170.37	152.98	640.58
Other expenses	374.99	422.60	358.74	1,544.30
Total expenses	2,613.78	2,497.87	2,310.18	9,667.63
3 Profit before exceptional item (1-2)	85.61	251.90	69.45	636.31
4 Exceptional items	-	-	-	-
5 Profit before share of profit of equity accounted investees and tax (3+4)	85.61	251.90	69.45	636.31
6 Share of profit/ (loss) of equity accounted investees	(0.39)	(2.08)	1.04	0.54
7 Profit before tax (5+6)	85.22	249.82	70.49	636.85
8 Tax expense				
Current tax	9.06	6.42	11.37	45.54
Current tax for earlier years	-	(1.73)	-	(1.73)
Deferred tax	(3.61)	(0.50)	(0.48)	(8.01)
Total tax expense	5.45	4.19	10.89	35.80
9 Profit for the period/ year (7-8)	79.77	245.63	59.60	601.05
10 Other comprehensive income/ (loss) for the period/ year				
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Remeasurement of net defined benefit liability	-	43.88	-	43.88
Income tax on items that will not be reclassified subsequently to profit or loss	-	(0.90)	-	(0.90)
<i>Items that will be reclassified subsequently to profit or loss</i>				
Exchange difference in translating financial statements of foreign operations	113.71	42.50	28.25	73.27
Income tax on items that will be reclassified subsequently to profit or loss	(35.48)	(13.21)	(8.81)	(22.80)
Other comprehensive income/ (loss), net of taxes	78.23	72.27	19.44	93.45
11 Total comprehensive income (9+10)	158.00	317.90	79.04	694.50
12 Profit attributable to :				
Owners of the Company	68.54	226.27	44.47	525.99
Non-controlling interests	11.23	19.36	15.13	75.06
Profit for the period/ year	79.77	245.63	59.60	601.05
13 Other comprehensive income/ (loss) attributable to :				
Owners of the Company	67.20	64.70	16.47	82.66
Non-controlling interests	11.03	7.57	2.97	10.79
Other comprehensive income/ (loss) for the period/ year	78.23	72.27	19.44	93.45
14 Total comprehensive income attributable to :				
Owners of the Company	135.74	290.97	60.94	608.65
Non-controlling interests	22.26	26.93	18.10	85.85
Total comprehensive income for the period/ year (12+13)	158.00	317.90	79.04	694.50
15 Paid-up equity share capital (Face value of INR 10 each)	497.27	497.22	497.11	497.22
16 Other equity	-	-	-	3,456.19
17 Earnings per share (Face value of INR 10 each)				
Basic (in INR)	Not annualised 1.38	Not annualised 4.55	Not annualised 0.89	Annualised 10.58
Diluted (in INR)	1.38	4.55	0.89	10.57

See accompanying notes to the statement of unaudited consolidated financial results



Aster DM Healthcare Limited
CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Segment details of unaudited consolidated financial results for the quarter ended 30 June 2022

(Amount in INR crores)

Particulars	Quarter ended (Unaudited)			Year ended
	30 June 2022	31 March 2022	30 June 2021	31 March 2022 (Audited)
		(refer note 5)		
1 Segment revenue				
Hospitals	1,519.76	1,503.82	1,370.51	5,773.58
Clinics	536.88	633.91	561.94	2,443.01
Retail pharmacies (including opticals)	600.08	577.18	436.46	2,013.44
Others	5.40	12.88	2.68	23.25
Total	2,662.12	2,727.79	2,371.59	10,253.28
2 Segment results before tax				
Hospitals	125.90	187.61	121.06	634.46
Clinics	38.95	83.18	57.92	292.90
Retail pharmacies (including opticals)	34.66	90.39	24.10	202.90
Others	0.49	0.46	0.60	2.29
Total	200.00	361.64	203.68	1,132.55
Less :				
Finance cost	(68.80)	(62.24)	(66.46)	(257.02)
Exceptional items	-	-	-	-
Share of profit of equity accounted investees	(0.39)	(2.08)	1.04	0.54
Other unallocable expenditure net of unallocable income	(45.59)	(47.50)	(67.77)	(239.22)
Profit before tax	85.22	249.82	70.49	636.85
3 Segment assets				
Hospitals	8,706.62	8,123.89	7,532.40	8,123.89
Clinics	1,910.58	1,835.12	1,793.50	1,835.12
Retail pharmacies (including opticals)	1,910.27	1,758.27	1,459.96	1,758.27
Others	46.37	17.20	16.85	17.20
Unallocated	539.67	811.76	1,050.61	811.76
Total	13,113.51	12,546.24	11,853.32	12,546.24
4 Segment liabilities				
Hospitals	4,519.37	4,008.93	3,752.26	4,008.93
Clinics	983.19	885.35	844.07	885.35
Retail pharmacies (including opticals)	1,102.96	978.08	840.30	978.08
Unallocated	1,891.45	2,191.26	2,503.43	2,191.26
Total	8,496.97	8,063.62	7,940.06	8,063.62

See accompanying notes to the statement of unaudited consolidated financial results

Notes to the statement of unaudited consolidated financial results for the quarter ended 30 June 2022:

- The statement of consolidated financial results ('the Statement') of Aster DM Healthcare Limited ('the Parent/ Company') and its subsidiaries (together referred to as 'the Group') and its share of profit in associates for the quarter ended 30 June 2022 has been reviewed by the Audit Committee and approved by the Board of Directors on 11 August 2022. The Statement has been subjected to review by Deloitte Haskins & Sells, the statutory auditor of the Company. The report of the statutory auditor is unmodified.
- During the quarter ended 30 June 2022, the Group has acquired 17.14% additional stake in the equity share capital of Sanghamitra Hospitals Private Limited for a purchase consideration of INR 20.49 crores.
- On the basis of detailed internal assessment carried out, the Management concluded that there is no requirement to retain the provision for contingent consideration payable to the erstwhile minority shareholders of one of the subsidiaries in GCC, in the books of accounts. Accordingly, the Group has recognized an income of INR 23.07 Crores arising out of the reversal of the contingent consideration provision.
- The Indian Parliament has approved the Code on Social Security, 2020 and Code on Wages, 2019 ['Codes'] relating to employee benefits during employment and post-employment benefits in September 2020 and the same has received Presidential Assent. The Codes have been published in the Gazette of India. However, the date on which the Codes will come into effect has not yet been notified. The Ministry of Labour and Employment (Ministry) has released the draft rules for the Code on 13 November 2020. The Group will give appropriate impact in its consolidated financial results in the period in which the Code becomes effective and the related rules are published.



Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -I, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Notes to the statement of unaudited consolidated financial results for the quarter ended 30 June 2022 (continued):

- 5) The figures for the quarter ended 31 March 2022 is balancing figure between audited figures in respect of year ended 31 March 2022 and the unaudited published figures in respect of nine months ended 31 December 2021, which was subjected to review by the statutory auditors.
- 6) Entities considered in preparation of the Statement are mentioned in Annexure A.
- 7) The Board of Directors ('Board') at their meeting held on 28 March 2022 constituted a Committee of Independent Directors ('Committee') of the Board to review the corporate structure of the Company and explore options for enhancing value ('Restructuring'). On 10 June 2022, the Board has provided their approval for appointment of the bankers to explore potential restructuring options which present an opportunity to unlock value for the Company and its stakeholders. Appropriate intimations and impact/ disclosures, if any, would be made as and when any conclusions are arrived at and approved by the Board.
- 8) Statements of unaudited standalone and consolidated financial results are available for perusal at the website of the Company and the stock exchanges.

For and on behalf of the Board of Directors of

Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Dr. Azad Moopen

Chairman and Managing Director
DIN 00159403

Kochi

11 August 2022



Aster DM Healthcare Limited
CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Annexure A to statement of consolidated financial results for the quarter ended 30 June 2022

Sl No	Entity	Relationship	Country of incorporation
1	Aster DM Healthcare Limited	Parent	India
2	DM Med City Hospitals (India) Private Limited	Subsidiary	India
3	Ambady Infrastructure Private Limited	Subsidiary	India
4	Aster DM Healthcare (Trivandrum) Private Limited	Subsidiary	India
5	Malabar Institute of Medical Sciences Limited	Subsidiary	India
6	Prerana Hospital Limited	Subsidiary	India
7	Sri Sainatha Multispeciality Hospitals Private Limited	Subsidiary	India
8	Dr. Ramesh Cardiac and Multispeciality Hospitals Private Limited	Subsidiary	India
9	Aster Clinical Lab LLP	Subsidiary	India
10	Hindustan Pharma Distributors Private Limited	Subsidiary	India
11	Affinity Holdings Private Limited	Subsidiary	Mauritius
12	EMED Human Resources India Private Limited	Step down Subsidiary	India
13	Ezhimala Infrastructure LLP	Step down Subsidiary	India
14	Warseps Healthcare LLP	Step down Subsidiary	India
15	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
16	Aster Ramesh Duhita LLP	Step down Subsidiary	India
17	Komali Fertility Centre LLP (earlier Ramesh Fertility Centre LLP)	Step down Subsidiary	India
18	Aster Caribbean Holdings Limited	Step down Subsidiary	Cayman Island
19	Aster Cayman Hospital Limited	Step down Subsidiary	Cayman Island
20	Aster DM Healthcare FZC	Step down Subsidiary	UAE
21	Aster Hospital Sonapur L.L.C	Step down Subsidiary	UAE
22	Radiant Healthcare L.L.C	Step down Subsidiary	UAE
23	Aster Day Surgery Centre LLC	Step down Subsidiary	UAE
24	DM Healthcare (L L C)	Step down Subsidiary	UAE
25	Wahat Al Aman Home Health Care L.L.C.	Step down Subsidiary	UAE
26	Aster Grace Nursing and Physiotherapy LLC	Step down Subsidiary	UAE
27	Aster Pharmacies Group LLC	Step down Subsidiary	UAE
28	New Aster Pharmacy DMCC	Step down Subsidiary	UAE
29	Aster DCC Pharmacy LLC	Step down Subsidiary	UAE
30	Aster Al Shafar Pharmacies Group LLC	Step down Subsidiary	UAE
31	Rafa Pharmacy LLC	Step down Subsidiary	UAE
32	Aster Pharmacy LLC, AUH	Step down Subsidiary	UAE
33	Med Shop Drugs Store LLC	Step down Subsidiary	UAE
34	Alfa Drug Store LLC	Step down Subsidiary	UAE
35	Alfa One Drug Store LLC	Step down Subsidiary	UAE
36	Alfaone FZ-LLC	Step down Subsidiary	UAE
37	DM Pharmacies LLC **	Step down Subsidiary	UAE
38	Aster Opticals LLC	Step down Subsidiary	UAE
39	Medcare Hospital (L.L.C)	Step down Subsidiary	UAE
40	Premium Healthcare Limited	Step down Subsidiary	UAE
41	Dr. Moopens Healthcare Management Services LLC	Step down Subsidiary	UAE
42	Eurohealth Systems FZ LLC	Step down Subsidiary	UAE
43	Al Rafa Investments Limited	Step down Subsidiary	UAE
44	Al Rafa Holdings Limited	Step down Subsidiary	UAE
45	Alfa Investments Limited #	Step down Subsidiary	UAE
46	Active Holdings Limited	Step down Subsidiary	UAE
47	Al Rafa Medical Centre LLC	Step down Subsidiary	UAE
48	Dar Al Shifa Medical Centre LLC	Step down Subsidiary	UAE
49	Aster Primary Care LLC	Step down Subsidiary	UAE
50	Modern Dar Al Shifa Pharmacy LLC	Step down Subsidiary	UAE
51	Harley Street LLC	Step down Subsidiary	UAE
52	Harley Street Pharmacy LLC	Step down Subsidiary	UAE
53	Harley Street Medical Centre LLC	Step down Subsidiary	UAE
54	Harley Street Dental LLC	Step down Subsidiary	UAE
55	Grand Optics LLC	Step down Subsidiary	UAE
56	Zahrat Al Shefa Medical Center L.L.C	Step down Subsidiary	UAE
57	Samary Pharmacy LLC	Step down Subsidiary	UAE
58	Metro Meds Pharmacy L.L.C	Step down Subsidiary	UAE
59	Metro Medical Center L.L.C	Step down Subsidiary	UAE
60	Symphony Healthcare Management Services LLC	Step down Subsidiary	UAE
61	E-Care International Medical Billing Services Co. LLC	Step down Subsidiary	UAE



/



Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Annexure A to statement of consolidated financial results for the quarter ended 30 June 2022

SI No	Entity	Relationship	Country of incorporation
62	Al Raffah Hospital LLC	Step down Subsidiary	Oman
63	Al Raffah Pharmacies Group LLC	Step down Subsidiary	Oman
64	Oman Al Khair Hospital L.L.C	Step down Subsidiary	Oman
65	Dr. Moopen's Healthcare Management Services WLL	Step down Subsidiary	Qatar
66	Welcare Polyclinic W.L.L	Step down Subsidiary	Qatar
67	Dr. Moopens Aster Hospital WLL	Step down Subsidiary	Qatar
68	Sanad Al Rahma for Medical Care LLC	Step down Subsidiary	Kingdom of Saudi Arabia
69	Aster DM Healthcare WLL (earlier Aster DM Healthcare SPC)	Step down Subsidiary	Bahrain
70	Orange Pharmacies LLC	Step down Subsidiary	Jordan
71	Al Shafar Pharmacy LLC, AUH **	Step down Subsidiary	UAE
72	Aster DM Healthcare INC **	Step down Subsidiary	Philippines
73	Aster Medical Centre LLC**	Step down Subsidiary	UAE
74	Aster Kuwait Pharmaceuticals and Medical Equipment Company W.L.L **	Step down Subsidiary	Kuwait
75	MIMS Infrastructure and Properties Private Limited	Associates	India
76	Alfaone Medicals Private Limited	Associates	India
77	Alfaone Retail Pharmacies Private Limited	Associates	India
78	Mindriot Research and Innovation Foundation	Associates	India
79	Aries Holdings FZC	Associates	UAE
80	AAQ Healthcare Investments LLC	Associates	UAE
81	Aries Investments LLC	Associates	UAE
82	Al Mutamaizah Medcare Healthcare Investment Co. LLC	Associates	UAE

The principal place of business of all the entities listed above is the same as their respective countries of incorporation.

** represents subsidiaries which are in the process of being wound-up.

Although the percentage of voting rights as a result of legal holding by the Group is Nil, the Group has the power to appoint/replace all members of the Board of Directors. Consequently Group has control over the entity.

